Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: gout flare

Optimize Gout Management with the Latest Evidence-Based Guidance

Mary Beth Nierengarten  |  November 17, 2020

ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – GoutGout

FAST Results for Febuxostat Safety in Patients with Gout

Keri Losavio  |  November 12, 2020

ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of…

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020ACR Convergence 2020 – GoutCARES study

High Opioid Prescription Rates Seen in Emergency Department-Treated Gout

Kurt Ullman  |  November 2, 2020

Acute gout can be very painful, causing patients to seek treatment in the emergency department. A retrospective study of pain interventions for gout in Rhode  Island found that nearly 30% of patients received prescriptions for opioid medications over 30 months. Of these prescriptions, over 80% were for patients who had never been exposed to opioids…

Filed under:AnalgesicsConditionsGout and Crystalline Arthritis Tagged with:Goutopioid crisis

Bringing Consistency to Gout Terms & Concepts

Larry Beresford  |  November 2, 2020

The umbrella term crystalline disease covers arthritic conditions caused by deposition of crystals and associated inflammatory response, including erythema, edema and intense pain. The two most common crystal-induced arthropathies are gout, an arthritis secondary to inflammation caused by the presence of monosodium urate (MSU) crystals formed through high levels of serum urate, and calcium pyrophosphate…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:Gout

Akarat Phasura / shutterstock.com

The ACR Releases a New Gout Guideline

Susan Bernstein, with John FitzGerald, MD, PhD  |  June 15, 2020

In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Michele B. Kaufman, PharmD, BCGP  |  December 11, 2019

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis

Potential Link Between OA & Gout

Arthritis & Rheumatology  |  December 2, 2019

Monosodium urate (MSU) crystal formation, deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. These researchers examined the effects of human cartilage homogenates on MSU crystallization and MSU crystal-induced inflammation…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:Arthritis & RheumatologyGoutmonosodium urate crystalsosteoarthritis (OA)Research

New Draft Gout Guideline Released

Susan Bernstein  |  November 20, 2019

ATLANTA—The authors of the new draft ACR treatment guideline for the management of gout presented the draft guideline on Nov. 13 at the 2019 ACR/ARP Annual Meeting. Based on evidence from more than 130 published studies, there are 42 recommendations, of which 16 were strong, including 27 for urate-lowering therapy (ULT) management, 13 of which…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:2019 ACR/ARP Annual MeetingGout

A CT of the abdomen demonstrated numerous hypodense lesions present in both lobes of the liver, with the largest lesion measuring 2.0 x 3.1 cm.

Case Report: A Patient with Gout Develops Granulomatous Hepatitis

Raj Vachhani, MD, & Angelo L. Gaffo, MD, MSPH  |  November 16, 2019

Case Presentation A 45-year-old man with crystal-proven gout, poorly controlled diabetes and chronic kidney disease was lost to follow-up for six years and presented back to the VA clinic in the midst of a gout flare. He stated he had continued taking 100 mg of allopurinol daily, but his serum urate level was 13.8 mg/dL….

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Allopurinolgranulomatous hepatitis

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Mary Choy, PharmD, BCGP, FASHP  |  October 14, 2019

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:GoutGout Resource Center

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 17
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences